Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | BCR | P11274 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772508 | 0.79 | CYP3A4 (0.36) | MET | |
| SCHEMBL4778149 | 0.75 | HDAC8 (0.39) | ABL1BCRRECQLHSD17B10 | |
| SCHEMBL4776893 | 0.73 | SCD (0.39) | ABL1BCRRECQLHSD17B10KMT2A | |
| SCHEMBL4837579 | 0.72 | SCD (0.38) | RECQLHSD17B10KMT2AKDM4E | |
| SCHEMBL4779060 | 0.66 | CYP1A2 (0.42) | KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL4794759 | 0.66 | DPP4 (0.43) | KMT2AALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL4779485 | 0.65 | DPP8 (0.35) | — | |
| SCHEMBL4770020 | 0.64 | AKT1 (0.52) | KMT2AMEN1 | |
| SCHEMBL4779334 | 0.64 | — | — | |
| SCHEMBL4779275 | 0.63 | HDAC8 (0.65) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |